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KESAN UBATAN ANTIHIPERTENSI KE ATAS TEKANAN OKSIDATIF 
JANTUNG  TIKUS HIPERTENSI SPONTAN ARUHAN N-nitro-L-arginina metil 
ester (L-NAME) 
 
ABSTRAK 
 
Hipertensi adalah satu faktor risiko utama yang menyumbang kepada 
kardiovaskular, serebrovaskular dan kerosakan ginjal. Patogenesis hipertensi adalah 
multifaktorial dan sangat kompleks. Ketidakseimbangan status oksidan / antioksidan 
telah dicadangkan sebagai mekanisme patogen penting dalam tekanan darah tinggi dan 
juga kerosakan organ aruhan-tekanan darah tinggi terutamanya pada jantung. 
Memandangkan tekanan darah tinggi menyumbang kepada kerosakan organ, rawatan 
ubat antihipertensi bertujuan untuk mengurangkan bukan sahaja tekanan darah tetapi 
juga kerosahan organ aruhan-tekanan darah tinggi. Walau bagaimanapun, kesan ubat 
antihipertensi α2-adrenergic agonist (Clonidine) dan perencat Angiotensine-Converting 
Enzim (ACE) (Enalapril) ke atas tekanan oksidatif pada jantung belum dikaji secara 
terperinci. Oleh itu, kajian ini telah dijalankan untuk mengkaji kesan Clonidine dan 
Enalapril pada penanda tekanan oksidatif, enzim antioksidan, antioksidan bukan enzim 
dan nitrik oksida dalam jantung tikus hipertensi spontan (SHR) dan SHR diaruh 
perencat enzim sintesis nitrik oksida, N-nitro-L-arginina metil ester (SHR + L-NAME). 
Dalam fasa pertama kajian, perbandingan penanda tekanan oksidatif dan sistem 
pertahanan antioksidan dalam normotensif tikus Wistar Kyoto (WKY) dan SHR, serta 
WKY+L-NAME dan SHR+L-NAME dinilai. SHR mengalami hipertesi bermula 
xxvii 
 
minggu kelapan diiringi dengan peningkatan dalam penanda tekanan oksidatif TBARS 
dan PCO, peningkatan aktiviti CAT, GR dan GST, penurunan aktiviti GPx, peningkatan 
aras GSH dan pengurangan aras GSSG, nisbah GSH: GSSG, dan aras NO dalam 
jantung. Dalam WKY + L-NAME, perencatan NO sintase oleh L-NAME berjaya 
meningkatkan tekanan darah berterusan bermula pada minggu ke-20. Dalam model ini, 
aras TBARS dan PCO meningkat, aktiviti GPx menurun, aktiviti GR dan GST 
meningkat, aras GSSG meningkat dan NO menurun. Bagi SHR+L-NAME, nilai 
tekanan darah melebihi > 200 mmHg, mempamerkan keadaan hipertensi 
kronik. SHR+L_NAME menunjukkan peningkatan aras TBARS dan PCO, peningkatan 
aktiviti GR dan GST, pengurangan aktiviti GPx, peningkatan aras GSSG dan 
pengurangan NO. Dalam fasa kedua kajian, kesan rawatan Clonidine ke atas status 
oksidan / antioksidan dalam jantung SHR dan SHR+L-NAME dinilai. Rawatan 
Clonidine mengurangkan SBP dan meningkatkan aras TAS pada SHR dan SHR+L-
NAME, pengurangan TBARS pada SHR+L-NAME, pengurangan PCO, aktiviti GST 
dan meningkatkan aras GSH dan nisbah GSH : GSSG, dan aktiviti CAT pada SHR dan 
SHR+L-NAME, penurunan aras GSSG dalam SHR+L-NAME dan peningkatan aras 
NO dalam SHR. Dalam fasa ketiga kajian, kesan rawatan Enalapril ke atas status 
oksidan / antioksidan pada jantung SHR dan SHR+L-NAME dinilai. Rawatannya 
mengurangkan SBP, TBARS, PCO, aktiviti GR dan GST, dan meningkatkan aras TAS, 
GSH, nisbah GSH:GSSG dan aktiviti CAT  pada SHR SHR+L-NAME, pengurangan 
aras TBARS dan PCO pada SHR dan SHR+L-NAME, peningkatan aktiviti SOD pada 
SHR, peningkatan aktiviti CAT pada SHR dan SHR+L-NAME, peningkatan aktiviti 
SOD pada SHR dan pengurangan aras GSSG pada SHR+L-NAME.  Kesimpulannya, 
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kajian ini mencadangkan bahawa tekanan oksidatif mungkin memainkan peranan dalam 
perkembangan dan / atau pengekalan hipertensi dan ketidakseimbangan status oksidan / 
antioksidan pada jantung membawa kepada kerosakannya pada tikus hipertensi. 
Rawatan ubat antihipertensi seperti Clonidine dan Enalapril menambahbaik tekanan 
oksidatif pada jantung yang berkemungkinan mengelakkannya daripada kerosakan di 
samping peranannya untuk mengurangkan tekanan darah. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxix 
 
EFFECT OF ANTIHYPERTENSIVE DRUGS TREATMENT ON OXIDATIVE 
STRESS IN HEART OF N-nitro-L-arginine methyl ester (L-NAME) 
ADMINISTERED SPONTANEOUSLY HYPERTENSIVE RAT 
 
ABSTRACT 
 
Hypertension is a major risk factor contributing to cardiovascular, 
cerebrovascular and renal diseases. The pathogenesis of essential hypertension is 
multifactorial and highly complex. An imbalance in the oxidant/antioxidant status has 
been proposed as an important pathogenic mechanism in hypertension as well as 
hypertension induced organ damage including heart. As hypertension contributes to 
organ damage, antihypertensive drug treatment aims to reduce not only the blood 
pressure but also hypertension induced organ damage. However, the effect of 
antihypertensive drugs α2-adrenergic agonist (Clonidine) and Angiotensin-Converting 
Enzyme (ACE) inhibitor (Enalapril) on oxidative stress in heart has not been well 
studied. Therefore, this study investigate the effect of Clonidine and Enalapril on 
oxidative stress markers, enzymatic /non-enzymatic antioxidants and nitric oxide (NO)  
in heart of spontaneously hypertensive rat (SHR) and SHR administered NO synthase 
inhibitor, N-nitro-L-arginine methyl ester (SHR+L-NAME). In the first phase of study, 
the comparison of levels of oxidative stress markers and antioxidant defence system in 
normotensive Wistar Kyoto Rats (WKY) and SHR, as well as WKY+L-NAME and 
SHR+L-NAME was carried out. SHR developed hypertension by 8 weeks accompanied 
by increased in oxidative status markers TBARS and PCO levels, increased CAT, GR 
and GST activities, reduced GPx activity, enhanced GSH and GSSG level, reduced 
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GSH : GSSG ratio, NO level in heart. In WKY+L-NAME, the inhibition of NO 
synthase by L-NAME successfully developed hypertension by weeks 20 onwards. In 
this model there is an increased TBARS and PCO level, reduced GPx activity, enhanced 
GR and GST activities, increased GSSG level and reduced NO bioavailability. In 
SHR+L-NAME, the systolic blood pressure values exceed >200 mmHg, exhibit severe 
hypertensive condition.  SHR+L-NAME showed an increased TBARS and PCO level, 
enhanced GR and GST activity, reduced GPx activity, increased GSSG and reduced NO 
level compared to SHR . In the second phase of study, the effect of Clonidine treatment 
on oxidant/antioxidant status in heart of SHR and SHR+L-NAME was assessed. 
Clonidine treatment reduced the SBP and increased the TAS level in SHR and SHR+L-
NAME, reduced TBARS in SHR+L-NAME, reduced PCO level, GST activity and 
enhanced the level of GSH and GSH:GSSG ratio and CAT activity in SHR and 
SHR+L-NAME, reduced GSSG level in SHR+L-NAME, as well as increased NO level 
in SHR. In the third phase of study, the effect of Enalapril treatment on 
oxidant/antioxidant status in heart of SHR and SHR+L-NAME was assessed. It reduced 
the level of SBP, TBARS, PCO, GR and GST activities and increased the level of TAS, 
GSH, GSH:GSSG ratio and CAT activity in SHR and SHR+L-NAME,  enhanced SOD 
activity in SHR, and reduced GSSG level in SHR+L-NAME. In conclusion, this study 
suggested that the oxidative stress play a role in the development and/or maintenance of 
hypertension and the imbalance in oxidant/antioxidant status in heart might leads to its 
damage in hypertensive rats. Antihypertensive drugs treatment such as Clonidine and 
Enalapril ameliorate the oxidative stress in heart of hypertensive rats and thereby these 
drugs might prevent its damage in addition to their role in reducing blood pressure.
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 BACKGROUND OF THE STUDY 
 
Globally, nearly one billion people have hypertension; of these, two thirds are in 
developing countries. Hypertension kills nearly 8 million people worldwide every year 
and nearly 1.5 million people each year in the South-East Asia. (WHO, September, 
2011). In addition, seven million premature deaths have been attributed to hypertension 
(WHO, 2002).  In South-East Asia region, approximately one-third of adult population 
is this region has high blood pressure (WHO, September, 2011). The Sixth Reports of 
the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC VI) (1997) define hypertension or high blood pressure is 
said to be present if the blood pressure is persistently at or above 140/90 mmHg. 
Hypertension is a global disease burden due to its high prevalence.  
 
The World Health Organization (2002) reported that suboptimal blood pressure 
(>120 mm Hg SBP) is responsible for 62% of cerebrovascular disease and 49% of 
ischemic heart disease, with little variation by sex. In  recent  decades,  it  has  become 
increasingly  clear  that  the  development  of  stroke, ischemic  heart  disease,  and  
renal  failure  have  been attributed  by  hypertension.  Treating  hypertension  has been  
associated  with 40%  reduction  in  the  risk  of  stroke and about 15% reduction in the 
risk of myocardial infarction (WHO, 2003). 
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Ministry of Health, Malaysia (2008) through its Clinical Practice Guidelines : 
Management of Hypertension reported that there is a positive relationship between 
systolic blood pressure (SBP), diastolic blood pressure (DBP) and the risk of 
developing cardiovascular, cerebrovascular and renal diseases. Therefore the main aim 
of identifying and treating high BP is to reduce these risks. Hence BP should be 
measured at every chance encounter. The classification of high BP, although arbitrary, 
is useful as clinicians must make treatment decisions based on the measured BP and the 
patients’ associated cardiovascular/cerebrovascular risks and comorbidities. Table 1.1 
provides a classification of BP for adults (age 18 and older) which was adopted from a 
similar classification that being used by the WHO-ISH and these criteria are for subjects 
who were not on any antihypertensive medication and who are not acutely ill. 
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Table 1.1 : Classification of blood pressure for adults aged 18 and above. 
  
* The prevalence of hypertension in Malaysia is according to the report by Lim et al., 
2000. 
 
 
 
 
 
 
 
 
 
Category 
Systolic 
(mmHg) 
 
Diastolic 
(mmHg) 
Prevalence in 
Malaysia* 
Optimal < 120 and < 80 32% 
Prehypertension 120-139 and/or 80-89 37% 
Hypertension Stage 1 140-159 and/or 90-99 20% 
Hypertension Stage 2 160-179 and/or 100-109 8% 
Hypertension Stage 3 ≥180 and/or ≥110 4% 
4 
 
 
 
 
Various  risk  factors  have  been  associated  with  hypertension, which include 
age, sex, race, physical activity and socioeconomic  class.  Vast  majority  of  cases  of  
uncontrolled  hypertension  are  amongst  individuals who are more  than  60  years  of  
age. (Thomas et.al., 2005)   
 
In recent decades, growing evidence indicate that imbalance of oxidant-
antioxidant resulted in elevation of free radicals and their metabolites such as reactive 
oxygen species which plays an important role in the pathophysiology of hypertension 
(Zalba et al., 2001). However, there is still a debate whether oxidative stress is a cause 
or a result of hypertension. Oxidative stress promotes vascular smooth muscle cell 
proliferation and hypertrophy and collagen deposition, leading to thickening of the 
vascular media and narrowing of the vascular lumen. In addition, increased oxidative 
stress may damage the endothelium and impair endothelium-dependent vascular 
relaxation as well as increases vascular contractile activity (Grossman, 2008). All these 
effects on the vasculature may explain how increased oxidative stress can cause 
hypertension. 
 
As hypertension contributes to organ damage, antihypertensive drug treatment 
aims to reduce not only blood pressure values but also hypertension-induced organ 
damage including heart. Even though anti-hypertensive drug treatments have been 
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shown to reduce blood pressure and certain oxidative stress parameters, the studies 
concerned were not comprehensive as the antioxidant defence mechanism were not 
investigated in detail whereby only a few oxidative stress parameters were measured 
(Khanna et al., 2008, Guillermore et al., 2004). 
 
Therefore, this study attempts to examine the effect of antihypertensive drugs 
(Clonidine and Enalapril) on the reduction of blood pressure as well as oxidative stress 
markers and antioxidant status.  
 
1.2 LITERATURE REVIEW 
 
1.2.1 Free radicals and its formation 
 
Free radical is an atom or molecule that have unpaired electron orbiting around 
central nucleus. Usually, an atom is composed of a central nucleus containing positively 
charged protons and neutral neutrons and electrons in pairs orbiting around it. Free 
radicals are generally unstable and highly reactive because the unpaired electrons tend 
to form pairs with other electrons from another radical which further forms a covalent 
bond or with non-radical molecule by various interaction leading to chain reaction.  
 
Molecular oxygen (O2) is essential for the survival of aerobic organisms. In 
aerobic organisms, oxygen is converted to water and this aerobic energy metabolism 
relies on oxidative phosphorylation, a crucial process by which the oxido-reduction 
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energy of mitochondrial electron transport is eventually converted to the high-energy 
phosphate bond of ATP (Novo and Parola, 2008) 
 
An oxygen molecule (O2) undergoes electron reduction when metabolized in 
vivo as follows:  
 
Equation 1 
O2  +  e  +  H
+
                  HO2
. 
 (hydroperoxyl radical) 
 
Equation 2  
HO2
.  
                 H
+
  +  O2
.- 
(superoxide radical) 
 
Equation 3 
O2
.-
 +  2H
+ 
 +  e                     H2O2 (hydrogen peroxide) 
 
Equation 4 
H2O2  + e                    OH
-  
+ 
.
OH (hydroxyl radical) 
 
Equation 5 
.
OH  + e  +  H
+ 
                     H2O 
 (Gutteridge, 1995) 
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During this process, reactive oxygen metabolites are generated by the excitation 
of electrons secondary to addition of energy or interaction with transition elements. The 
reactive oxygen metabolites are continuously produced and highly reactive than the 
original oxygen molecule known as reactive oxygen species (ROS) (Apel and Hirt, 
2004). ROS includes oxygen ions, free radicals and peroxides both inorganic and 
organic, which includes superoxide anions (O2
.-
), hydroxyl radical (
.
OH), hydrogen 
peroxides (H2O2), hydroperoxyl radical (HO2
.
), peroxyl radical (RO2
.
), alkoxyl radical 
(RO
.
), hypochlorite (HOCl
-
) and hypochlorus acid (HOCl). There are also another 
group of free radicals, which are known as reactive nitrogen species (RNS). RNS 
includes nitric oxide (NO or NO
.
), nitrogen dioxide (NO2
.
), peroxynitrite (ONOO
-
), 
peroxynitrous acid (ONOOH), alkyl peroxinitrite (ROONO) and s-nitrosothiols 
(RSNO).  
 
1.2.1.1 Superoxide anion (O2
.-
 ) 
 
Superoxide  anion  (O2
.-
 ) is  fairly  abundant  and  approximately  2%  of  the 
oxygen consumed by cells is converted into O2
.-
. Superoxide anion, O2
.-
 is mainly 
formed in vivo by the electron transport chains in the mitochondria and microsomes 
through electron leakage, a phenomenon that occurs with an increase in O2 utilization 
(Cui et al., 2004). Besides, oxygen also undergoes univalent reduction to form 
superoxide anion (O2
.-
) by enzymatic action of nicotinamide adenine dinucleotide 
phosphate (NADH/NAD(P)H) oxidases and xanthine oxidases (XO). Oxygen can also 
become O2
.-
 by non-enzymatic reaction with redox active compound such as 
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semiubiquinone of the mitochondrial electron transport chain. (Fridovich, 1978). 
Superoxide anion possesses different properties depending on the pH and environment. 
Due to its pKa of 4.8, superoxide anion can exist in the form of either O2
.-
 or, at low pH 
, hydroperoxyl (HO2
.
) (Halliwell and Gutteridge, 1999). Superoxide anion, O2
.- 
is a 
weak oxidizing agent in aqueous solution and is able to oxidize molecules such as 
ascorbic acid and thiols. In contrary, O2
. - 
is a much stronger reducing agent and can 
reduce several iron complexes such as cytochrome c and ferric-EDTA. (Gutteridge, 
1995). Hydroperoxyl can therefore be considered an important species, although under 
physiological pH most of the superoxide is in the charged form. (Shiriska and Mastan, 
2013). Superoxide anion is short lived owing to its rapid reduction to become hydrogen 
peroxide (H2O2) through the action of superoxide dismutases (SODs).  
 
Equation 6 : O2
.-
 + O2
.- 
 + 2H
+
                 H2O2 + O2 
 
In biological tissues, O2
.-
 can also undergo nonenzymatic transformation into H2O2 and 
singlet oxygen (
1
O2 ) (Steinback et. al, 2013) 
 
1.2.1.2 Hydrogen peroxide (H2O2) 
 
The result of the dismutation of superoxide radicals is the production of  H2O2. 
However, H2O2 can be produced directly by the transfer of two electrons to oxygen by 
many enzymes such as urate oxidase, glucose oxidase, and D-amino acid oxidase 
produce (Gutteridge, 1995). The same report also reported that H2O2 is a weak oxidant 
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and reducing agent that are relatively stable in the absence of transition metal ions. 
Besides, H2O2 is uncharged which can easily diffuse across biological membranes, a 
non-radical potent oxidizing agent and able to oxidize or reduce several inorganic ions 
in aqueous solutions (Halliwell and Gutteridge, 1989, Gutteridge, 1995). 
 
Damage occurs when H202 interact with reduced form of transition metals such 
as Fe
2+
 or Cu
+
. These process will further decompose the hydrogen peroxide to yield the 
highly reactive hydroxyl radical (
.
OH) via the Haber-Weiss of Fenton reaction (Cui et 
al., 2004). Myeloperoxidase, a heme protein secreted by phagocytes, can amplify the 
oxidative potential of H2O2 involved in the formation of hypochlorous acid (HOCl) and 
singlet oxygen, (
1
O2) (Schraufstatter et al., 1990, Tatsuzawa et al., 1999). Unwanted 
H2O2 is removed from cells by the action of antioxidant enzymes either catalase or 
glutathione peroxidase through conversion to water molecules. (Griendling and  
FitzGerald 2013) 
 
1.2.1.3 Hydroxyl radical (
.
OH) 
 
The hydroxyl radical (
.
OH) is an extremely aggressive oxidant that indiscriminately 
attack most biological molecules at an almost diffusion controlled rate involving three 
main chemical  reactions; hydrogen abstraction, addition reaction  and  electron  
transfer. (Halliwell and Gutteridge, 1989). Hydroxyl radical, 
.
OH is a potent oxidizing 
agent that can counter at a high rate with most organic and inorganic molecules in the 
cell, containing DNA, proteins, lipids, amino acids, sugars, and metals (Gutteridge, 
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1995). The main reaction for 
.
OH formation is known as the Fenton reaction. In this 
reaction, H2O2 react with transition metal such as Fe
2+
 or Cu
+
 to produce highly reactive 
hydroxyl radicals (
.
OH).  
 
Equation 7 : H2O2  + Fe
2+
 / Cu
+
               
.
OH   + Fe
3+
 / Cu
2+ 
 
Hydroxyl radical, 
.
OH can be produced when superoxide anion (O2
.-
) and 
hydrogen peroxide react together in the iron-catalyzed reaction (Young and Woodside, 
2001).  
 
Equation 8 :  Fe
3+
 / Cu
2+
 +   O2
.-
              Fe
2+
 / Cu
+  
+  O2 
Equation 9:  Fe
2+
 / Cu
+ 
+ H2O2                    Fe
3+
 / Cu
2+ 
 +  
.
OH  + OH
- 
 
These reactions produce nett reaction known as Haber-Weiss reaction, which 
leads to the production of hydroxyl radical in vivo. 
 
Equation 10 :    O2
. 
   +   H2O2                      
.
OH  + OH
-  
+  O2 
 
1.2.1.4 Nitric Oxide (NO
.
) 
 
Nitric  oxide  (NO•)  is  an  abundant  reactive  radical  that  act  as  an important 
oxidative biological signaling molecule in a large variety of diverse physiological  
processes,  including  neurotransmission,  blood  pressure regulation,  defense  
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mechanisms,  smooth  muscle  relaxation  and  immune regulation (Patel et al., 2000). 
Nitric oxide, NO is an uncharged lipophilic molecule that contains a single unpaired 
electron (NO•) which causes it to be reactive either as an electron donor (oxidant) or an 
electron acceptor (antioxidant) (Drew and Leeuwenburgh, 2002).  Half-life of nitric 
oxide is only a few seconds due to rapid degradation by the superoxide anion. 
Superoxide anion is a major determinant of nitric oxide (NO) biosynthesis and 
bioavailability and which may modify endothelial function and result in vasoconstrictor. 
(Ceriello, 2008).  
 
NO is produced within cells by the actions of a nitric oxide synthases which 
metabolize arginine to citrulline with the formation of  NO•  via  the  five-electron  
oxidative  reaction. There are three distinct isoforms of nitric oxide synthase: neuronal 
(nNOS or NOS-1), inducible (iNOS or NOS-2), and endothelial (eNOS or NOS-3) 
(Drew and Leeuwenburgh, 2002). Nitric oxide synthase (NOS), and in particular the 
endothelial isoform of NOS (eNOS), is identified as an important source of superoxide 
(Martasek et al., 1998, Ferroni et al., 2004). eNOS can generate superoxide rather than 
NO in response to atherogenic stimuli has led to the concept of ―NOS uncoupling‖. 
NOS uncoupling is said to be present when the activity of the enzyme for NO 
production is decreased, in association with an increase in NOS dependent superoxide 
production (Landmesser et al., 2003). 
 
 
 
12 
 
 
1.2.1.5 Peroxynitrite anion (ONOO
-
) 
 
Peroxynitrite anion (ONOO
−
) is formed by the reaction of nitric oxide and the 
superoxide anion. Cells of the immune system produces O2
.- 
and NO• during oxidative 
burst triggered during inflammatory processes which further produce peroxynitrite 
anion (ONOO
−
), a potent oxidising agent that can cause DNA fragmentation and lipid 
oxidation (Carr et al, 2000) 
 
Equation 11 : NO•  +  O2
.-           
        ONOO
−
 
 
ONOO
− 
is a powerful oxidant, which is able to damage many biological 
molecules, and decompose at acidic pH to release small amounts of hydroxyl radicals 
independent of metal catalysis (Equation 12) (Gutteridge, 1995) 
 
Equation 12 : ONOO
-
   + H
+
                     
.
OH  + NO2 
 
Peroxynitrite may react directly with diverse biomolecules such as CO2 to form 
highly reactive nitrous peroxocarboxylate  (ONOOCO2
-
),  or  protonated  as  
peroxinitrous  acid (ONOOH). (Augusto et al, 2002). The  protonated  form  of  
peroxynitrite  (ONOOH)  is  a  powerful oxidizing agent similar to OH•, which might 
cause depletion of sulfhydryl groups and oxidation of  many  molecules (Kohen and 
Nyska, 2002). This  can  also  cause  DNA  damage  including  strand breaks,  protein  
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oxidation and  nitration  of  aromatic  amino  acid  residues  in  proteins  such as  3-
nitrosotyrosine (Rubbo et al., 2000). Under physiological conditions, ONOOH can react 
with other  components  present  in  high  concentrations,  such  as  H2O2 or  CO2,  to 
form an adduct that might be responsible for many of the deleterious effects  seen in 
biological sites (Czapski and Goldstein, 1995; Beckman and Koppenol, 1996). 
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Figure 1.1 : Vascular ROS. Highlighted in gray are some of the most important ROS in 
vascular cells. Oxygen is converted to O2
.
 by oxidases, which is further dismutated to 
H2O2 by superoxide dismutase (SOD). H2O2 can be converted to H2O by enzymatic 
action of catalase or glutathione peroxidase (GSH-Px), or through transition metal 
binding reaction with Fe
2+ 
to produced hydroxyl radical (·OH). In addition, O2
.
reacts 
rapidly with nitric oxide (NO·) to form peroxynitrite (OONO
-
). (Griendling and 
FitzGerald, 2003).  
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1.2.2 Oxidative damage to lipid, protein and DNA 
 
ROS and RNS are formed through variety of event and pathways. Previous 
research by Beckman and Ames (1997) estimated that one human cell is exposed to 
approximately 1.5×10
5
 oxidative hits per day from superoxide, hydroxyl radicals, 
hydrogen proxide and other  such  reactive  species (Beckman and Ames, 1997).  Free 
radical has high potential to oxidize the biomolecules such as lipid, protein and DNA, 
leading to damage of biomolecules, termed oxidative damage (Halliwell, 2007; Seven et 
al., 2008). 
 
Cell membranes are the major site of lipid peroxidation as they contain 
polyunsaturated fatty acid residues of phospholipids that is sensitive to oxidation (Valko 
et al., 2005). Extensive lipid peroxidation in biological membranes causes alteration in 
fluidity, decreased membrane potential, increased permeability as well as cell rupture. A 
report by Valko et al., 2005 discussed that the overall lipid peroxidation process 
involved initiation, propagation and termination stages. The lipid peroxidation process 
was initially started with ROS abstracting a hydrogen atom from methylene group in the 
lipid. Furthermore, the fatty acid radical can react with oxygen that is present in the 
surrounding tissue formed lipo-peroxyl radicals (ROO
.
) during the propagation stage. 
ROO
. 
are very reactive, and can abstract another hydrogen from the neighboring fatty 
acid produce hydroperoxide (ROOH). ROOH, either being converted to unreactive fatty 
acid alcohols through reducion by glutathione peroxidases, or react with redox metals to 
produce reactive product such as aldehydes and epoxides. Lipid peroxidation process 
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was ended like other chain reaction termination process, which is by combination of 
two radicals to become non radicals or depletion of the substrate. Malondialdehyde 
(MDA) and 4-hydroxynonenal (HNE) are examples of major aldehyde product of lipid 
peroxidation (Marnett, 1999). TBARS test are commonly used as indices of lipid 
peroxidation and peroxidative tissue injury. This test is predicated upon the reactivity of 
thiobarbituric acid (TBA) towards MDA (Janero, 1990).  
 
Oxidation of protein may occur through several processes including oxidation of 
protein backbone, protein fragmentation or oxidation of amino acid side chains (Berlett 
and Stadman, 1997). Hydroxyl radical (
.
OH) abstracts the hydrogen atom of an amino 
acids residue to form carbon-centered radical in oxidative modification on polypeptide 
backbone. The carbon-centered radical reacts with oxygen to form alkylperoxyl radical 
intermediate, followed by alkylperoxide, alkoxyl radical and converted to hydroxyl 
protein derivative. Alkoxyl radicals, an intermediate product of protein backbone 
oxidation, may also cause protein fragmentation through cleavage of peptide bond by 
either diamide or α-amidation pathways. Furthermore, all amino acid residues of protein 
mainly cystein and methione are susceptible to oxidation of their side chains. Oxidation 
of amino acid residues and/or peptide backbone of proteins results in the generation of 
protein carbonyl group (Marnett et al., 2003). The presence of protein carbonyl has 
been used  as a marker of protein oxidation (Levine et al., 1994). 
 
ROS/RNS may also attack DNA bases or deoxyribose residues to produce 
damage bases or strand breaks (Hall et al., 1996; Cooke et al., 2003). 
.
OH is highly 
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reactive can attack the double bonds of DNA bases or abstract hydrogen atom from the 
methyl group of thymine and each of C-H bonds of 2’deoxyribose (Halliwell, 1991). 
Cellular DNA damage under prooxidant condition has also been reported to be 
mediated by iron. In fact, iron binds nucleic acids very well and DNA is a favored target 
of Fenton-mediated damage (Imlay, 2003). Guanine base is the most easily oxidized 
and serves as a major target of oxidative nucleic acid within the cell (Hall et al., 1996). 
Hydroxyl attack to the deoxyguanosine resulted in the formation of 8-hydroxy-2’-
deoxyguanosine, which is the most used marker for DNA lesion (Shigenaga and Ames, 
1991). The resultant damage to DNA bases may be a significant source of mutations 
that lead to cancer and other human pathology (Nicolic et al., 2006). 
 
Whether ROS/RNS attacks these targets significantly depends upon the delicate 
balance between the level of oxidant and antioxidants. In fact, increase in ROS 
formation is a signal which activates redox homeostasis through upregulation of 
antioxidant enzymes activity to retain the redox balance (Young and Woodside, 2001). 
 
1.2.3 Antioxidant defence system 
 
Under normal physiological condition, the rate of oxidant formation is balanced 
by the rate of oxidant elimination though antioxidant defence mechanism. According to 
Halliwell and Gutteridge (1989), an antioxidant is any substance that when present at 
low concentration compared to that of an oxidizable substrate significantly delays or 
inhibits oxidation of that substrate. Cells are equipped with enzymatic and 
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nonenzymatic antioxidant systems to eliminate oxidant and maintain redox homeostasis 
(Trachootham et al., 2008).  
 
1.2.3.1 Enzymatic antioxidants 
 
The first line of antioxidant defence in cell is provided by antioxidant enzymes 
(Rodriguezl et al., 2004).  The primary antioxidant defense mechanism is provided by 
three main antioxidant enzymes such as superoxide dismutase, catalase and glutathione 
peroxidase (Meydani, 2001). These antioxidant systems are widely distributed in nature, 
underlining their importance in preventing the damaging effects of reactive oxygen 
metabolites in biological systems with high specific cellular content (Sies, 1991). 
Another set of enzymatic antioxidants, glutathione reductase (GR) and glutathione-S-
transferase (GST) which are the component of glutathione (GSH) system also plays a 
vital role in maintaining oxidant/antioxidant system (Lee et al., 2010). 
 
1.2.3.1.1 Superoxide dismutase (SOD) 
 
The ﬁrst enzymatic reaction in the reduction pathway of oxygen occurs during 
the dismutation of two molecules of O2 when they are converted to hydrogen peroxide 
(H2O2) and diatomic oxygen (Equation 6). The enzyme at this step is one of the three 
types of superoxide dismutase (SOD); CuZnSOD is present in the cytosol, MnSOD is 
located in the mitochondrial matrix, and extracellular SOD (EC-SOD) is present in 
interstitial spaces and extracellular fluids (Landis and Tower, 2005). 
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SOD dismutate O2
.-
 by successive oxidation and reduction of the transition metal 
ion at the active site in a Ping Pong type mechanism with remarkably high reaction rates 
(Meier et al., 1998). The same report also reported that SOD are metalloproteins, 
containing Cu
2+
 , Ni
3+
 , Fe
3+
 or Mn
3+
  as active metal cofactor. 
 
The first type of SOD, Cu/Zn-SOD has two identical subunits with molecular 
mass of approximately 32 kDa (Battistoni et al., 1996). Each subunit contains a metal 
cluster, an active site, constituted by a copper and a zinc atom bridged by a histamine 
residue (Battistoni et al., 1998). Cu/Zn-SOD is very stable and possess a compact 
structure that is highly resistant to denaturing agents such as urea, SDS and proteolytic 
enzymes. Moreover, several diseases are associated with defects in CuZnSOD 
(MacMillan-Crow and Cruthirds, 2001). 
 
Mitochondrial Mn-SOD  is  a  tetramer with molecular weight approximately 96 
kDa, containing one manganese atom per subunit. This enzyme cycles  from  Mn
3+
  to  
Mn
2+
  and  back  to  Mn
3+
  during  the  two  step dismutations of superoxide 
(MacMillan-Crow et al., 1998). Mn-SOD greatly  induced  and  depressed  by  
cytokines,  but  moderately  influenced  by  oxidants  (Stralin and Marklund,1994). 
 
Another type of SOD is extracellular SOD (EC-SOD) which is a secretory, 
tetrameric, copper  and  zinc  containing  glycoprotein,  with  a  high  affinity  for  
certain glycosaminoglycans  such  as  heparin  and  heparin  sulphate (Mates et al., 
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1999).  In mammalian tissue, this type of SOD is coordinated by cytokines rather than 
as a response of individual cell to oxidants.  
 
 
1.2.3.1.2 Catalase (CAT) 
 
Catalase (EC 1.11.1.6) is a tetrameric enzyme consists of four identical 
tetrahedrally arranged subunits of 60 kDa which contributes to overall molecular weight 
of 240 kDa and contains a single ferriprotoporphyrin group per subunit (Aebi, 1980). It 
is abundantly located within cells in peroxisomes, which also contain most of the 
enzymes capable generating H2O2 (Schrader and Fahimi, 2006). CAT can react with 
hydrogen donors such as methanol, ethanol, formic acid, or phenols with peroxidase 
activity in addition to its main reaction to catalyze conversion of H2O2 to form water 
and molecular oxygen (Mates et al., 1999). Two stages are involved in this conversion : 
 
Equation 13 :   CAT-Fe
3+
   + H2O2                            compound I 
 
Equation 14 :   compound I + H2O2                           CAT-Fe
3+
  + 2H2O   + O2 
 
CAT has high KM for its substrate and can remove H2O2 present in high 
concentrations (Kohen and Nyska, 2002). CAT has one of the highest turnover rates for 
all enzymes: one molecule of CAT can convert more than 6 million molecules of 
hydrogen peroxide to water and oxygen each minute. Although it has a very large 
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capacity to destroy H2O2, its affinity for H2O2 is low. Even though CAT is not essential 
for some cell types under normal conditions, it plays an important role in the acquisition 
of tolerance to oxidative stress in the adaptive response of cells (Mates et al., 1999). 
 
 
1.2.3.1.3 Glutathione peroxidase (GPx)  
 
Glutathione peroxidase (EC 1.11.1.19) consists of four identical subunits with 
overall molecular weight of 80 kDa. Each subunit contains a single selenocysteine 
residue, which is essential for enzyme activity (Tappel, 1978). GPx is the most 
abundant peroxidase present in both cytosol and mitochondria which catalyzes the 
reduction of H2O2 to water molecule in which glutathione (GSH) is oxidized to oxidized 
glutathione (GSSG) (Rodriguez et al., 2004). 
 
In contrast to catalase, peroxidase possesses high affinity for H2O2 and the 
catalytic actions may takes place even in low concentration of H2O2 (Halliwell and 
Gutteridge, 1999 ). In addition, oxygen is not produced in the latter reaction which 
distinguishes the activity of peroxidase from catalase. However, the electron donors in 
these reactions are small molecules, such as glutathione or ascorbate (in plants). The 
removal of H2O2 through this reaction consumed two molecules of glutathione to 
remove one molecule of H2O2 (Kohen and Nyska, 2002). 
 
Equation 15 : 2GSH  + H2O2      
Peroxidase
       GSSG    +   2H2O  
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Although GPx shares the same substrate with CAT which is H2O2, GPx alone 
can react effectively with lipid and other organic hydroperoxides. GPx is the major 
source of protection against low level of oxidative stress. (Kohen and Nyska, 2002). 
 
 
1.2.3.1.4 Glutathione reductase (GR)  
 
GR (EC 1.6.4.2) is a dimer of two identical subunits of molecular mass 50 kDa 
each. GR has a similar tissue distribution to glutathione peroxidase, which is mainly 
located in the cytosol (Himeno., 1993). GR is a ﬂavoprotein, which uses NADPH as an 
electron donor for the reduction of GSSG (Gutterer et al., 1999). The oxidised form of 
glutathione (GSSG) may be converted back to the reduced form (GSH) by the activity 
of enzyme glutathione reductase (GR).  
 
Equation 16 :  GSSG + NADPH + H
+
          
GR
            2GSH +  NADP
+ 
 
NADPH is usually formed by pentose phosphate pathway and required to 
replenish the supply of reduced glutathione (Champe, 2008). Any competing pathway 
that utilizes NADPH such as the aldose reductase pathway might lead to a deficiency of 
reduced glutathione and hence impair the action of glutathione peroxidase (Gutterer et 
al., 1999). 
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1.2.3.1.5 Glutathione S-transferase (GST) 
 
Glutathione S-transferases (EC 2.5.1.18) are thought to play a physiological role 
in initiating the detoxication of potential alkylating agents, xenobiotics, 
chemotherapeutic agents, and some other pharmacologically active compounds 
(Manncrvick et al., 1985; Daniel, 1993). GST catalyzes the conversion of electrophilic 
compounds such as carcinogens and exogenous drugs with the presence of glutathione, 
and produce less toxic and more readily excreted metabolites (Manncrvick et al., 1985). 
The α, µ, π and θ are four classes of isoenzymes in GST superfamily which are encoded 
by different genes at different loci in the chromosomes and display peculiar structural 
and functional characteristics (Daniel, 1993).  
 
Glutathione  conjugates  are  metabolized  by  cleavage  of  glutamate  and  
glycine residues,  followed  by  acetylation  of  the  resultant  free  amino group  of  
cysteinyl  residue,  to  produce a mercapturic  acid. The mercapturic  acid  such as S-
alkylated derivatives  of  N-acetylcysteine, is then  excreted (Boyland and Chasseaud, 
1969; Habiq et al., 1974). 
 
The regulation of GST activity is complex as they exhibit sex, age, species and 
tumor specific pattern of expressions (Heyes and Pulford, 1995). GST activity may be 
regulated in vivo by ROS, because GST is one of the most potent inducers capable of 
generating free radicals by redox-cycling, as well as accumulation of H2O2 which result 
in induction of GST in mammalian cell (Arthur et al., 1987). 
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1.2.3.2 Non-enzymatic antioxidants 
 
Another major group of antioxidant system of a cell is the non-enzymatic 
antioxidant. Non-enzymatic antioxidants are divided into two types, which are the chain 
breaking antioxidant and transition metal binding protein. As free radicals tend to 
interact with another molecule and generate another radical, chain breaking antioxidants 
will neutralize the radicals produced with the formation of stable byproduct (Gutteridge, 
1995). Transition metal binding proteins such as ferritin, transferring, lactoferrin and 
ceruloplasmin also act as crucial components of the non-enzymatic antioxidant defence 
system by sequestering iron and copper so that they are not available to drive the 
formation of hydroxyl radicals (Kohen and Nyska, 2002). This section will focus on 
glutathione, an example of chain breaking antioxidant as this compound has a major 
impact on cellular respiration because it gathers and gives off hydrogen within the body 
and is part of the metabolic process.  
 
Glutathione (GSH : γ-L-glutamyl-L-cysteinylglycine) is the most abundant 
intracellular non-protein thiol present in mammalian cells (Sies, 1999). GSH is now 
known to function directly or indirectly in many important biological phenomena, 
including the synthesis of proteins and DNA, transport, enzyme activity, metabolism, 
and protection of cells (Meister and Anderson, 1983). The location of GSH in the 
nucleus maintains the redox  state  of  critical  protein  sulphydryls  that  are  necessary  
for  DNA  repair  and  expression (Masella et al., 2005). 
